UK Medtech Strategy Puts Innovation at the Centre

UK Medtech Strategy Puts Innovation at the Centre

MedTech Outlook | Tuesday, May 09, 2023

The UK medtech strategy focuses on IP protection, R&D funding, and agile regulation to support innovation, enhance productivity, and drive economic growth.

FREMONT, CA: The UK Department of Health and Social Care has released a medical technology strategy to hasten the accessibility of innovative technologies for patients. The strategy aims to facilitate accelerated diagnosis, treatment, and care delivery to patients, freeing up clinicians' time. It is based on the lessons learned during the Covid-19 pandemic, which saw the rapid development of new medical technologies. The ultimate goal is to ensure that the appropriate medical products are readily available to patients, in the right place and at the right terms.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

Medtech is a Vital UK industry

In the UK, healthcare spending makes up around 12 per cent of the GDP, with a significant portion of the expenditure going towards medical technology. The NHS alone spends approximately ten billion euros each year on medtech products including surgical equipment, implants, prostheses, wound dressings, syringes, medical imaging devices, and cardiac pacemakers.

Medtech Innovation and IP

The main objective is to promote innovative research and attract investments in the UK economy by securing and examining intellectual property to protect their concepts and advancements. Innovators can benefit from their investment in R&D. The extent of patent applications and other IP filings stemming from R&D operations is a reflection of innovation.

Why Securing IP Protection is Important for Medtech Innovators

Innovative medtech companies can create a strong monopoly and prevent competition from entering certain healthcare markets by developing an extensive IP portfolio. They can then earn revenue through licensing and benefit from their R&D investment. The ability to monetize IP rights generates a significant income stream. Due to the lengthy process of developing and gaining regulatory approval for medical devices, the intellectual property (IP) portfolio of a new market player or startup is often its most significant asset. Furthermore, research suggests that the use of IP can lead to better company performance, as owning IP rights is closely linked to enhanced economic performance at the firm level.

What types of IP Rights can be acquired?

Intellectual property (IP) rights refer to patents, design rights, trademarks, copyright, and trade secrets, all of which can be beneficial in safeguarding a medical device. Among these, obtaining a granted patent in commercially significant regions is often viewed as the most valuable form of IP protection and can provide the widest monopoly. For medical devices, patents can cover specific characteristics of the device itself, as well as the manufacturing processes used to create the device.

Furthermore, obtaining patents is also possible for the way a medical device is utilised, which is especially significant for connected devices that transfer data from the medical device to another part of a system for analysis. The process by which data is collected, processed, and transmitted by the medical device or a connected component of the system may also be protected. The development of AI is one such advancement that has led to the submission of many patent applications in this area.

UK Initiatives Supporting IP Development and Innovation

The UK government offers several initiatives to support businesses in their research and development efforts, as well as their intellectual property development. One of these initiatives is the UK Intellectual Property Office's IP Audits Plus service, which provides funding to small and medium-sized enterprises (SMEs) for an IP audit. This audit helps SMEs identify and evaluate their existing and potential IP assets, enabling them to understand their relevance to the broader business strategy and increase their commercial value. SMEs receiving the funding can engage any qualified IP professional based in the UK to carry out the audit.

The UK government has introduced several initiatives to encourage the generation and retention of intellectual property (IP). One such initiative is Patent Box, which offers a reduced tax rate for businesses on profits related to qualifying IP income. The goal of this program is to promote the commercialisation of inventions by UK-based companies and keep IP in the UK.

Looking to the Future

The medtech sector in the UK is showing a positive trend in terms of innovation and is expected to play a vital role in driving the economy forward and recovering from the effects of the Covid-19 pandemic. The majority of medtech innovators in the UK are small and medium-sized enterprises (SMEs), hence these businesses must be given the necessary financial support and resources to flourish.

To facilitate this growth, it is crucial to create a conducive environment that fosters innovation instead of hindering it. Government policies can play a pivotal role in this regard by providing access to funding and by establishing a suitable legislative framework for the medtech industry that protects and promotes IP generation for medtech innovators.

The success of the medtech sector in the UK is essential for driving economic growth and recovery in the aftermath of the Covid-19 pandemic. As most of the UK's medtech innovators are SMEs, they must receive adequate funding and support to prosper. An environment that fosters innovation and a regulatory system that facilitates the introduction of new medical devices may significantly impact the medtech sector's growth. Supporting initiatives such as the UKIPO IP audit service and Patent Box can help ensure that UK medtech businesses have the resources they need to innovate and thrive. By providing the necessary backing to the medtech industry, productivity across the economy can be enhanced, leading to job creation, economic growth and overall prosperity in all parts of the UK.

The government's medical technology strategy aims to accelerate access to innovative technologies and improve patient care while freeing up clinician time. It recognises the importance of intellectual property (IP) in protecting innovations and creating a valuable income stream for businesses. Patents are considered the most valuable form of IP protection, especially for medical devices, where they can cover unique device features, manufacturing processes, and usage methods. Various UK government initiatives, including IP Audits Plus and Patent Box, support R&D and IP development for businesses. Supporting medtech innovation in the UK is essential for economic growth and recovery, and agile regulatory systems and continued funding for SMEs are necessary to achieve this. Ultimately, cultivating a culture of innovation across the UK medtech industry will enhance productivity and bring jobs, growth, and prosperity to the country.

More in News

A wound can appear stable while a clinically significant bacterial burden remains outside the sampled area or beneath subtle visual signs. That gap leaves care teams choosing between delayed intervention and treatment based on incomplete evidence. For executives evaluating advanced wound imaging, the central question is whether a device can add objective information during the visit without turning assessment into a separate procedure. Visual inspection still carries unavoidable limits. Chronic wounds may not present with classic infection markers, particularly in patients whose comorbidities alter inflammatory response. Erythema can also be harder to identify across darker skin tones. Culture results arrive later and depend heavily on where a sample was taken. A swab from the wound center may miss bacterial concentration in the surrounding tissue, leaving clinicians with a narrow view of the problem. Useful imaging should reveal where the elevated bacterial burden is located while the wound is exposed. Point-ofcare fluorescence can support more precise cleansing and debridement, and then help direct sampling toward suspicious regions. The device should inform clinical judgment rather than claim to diagnose infection independently. Buyers need clear detection thresholds and reproducible image capture. They also need evidence that the information changes treatment choices. Measurement quality carries equal weight. Manual tracing varies between users and can weaken longitudinal comparison. Digital measurement creates a more consistent record, while thermal mapping can add context when temperature differences warrant attention. Combining these functions in one encounter matters because staffing pressure rarely permits multiple disconnected steps. Portability also affects use. A handheld system is easier to bring to the bedside, but a compact design cannot excuse difficult positioning or inconsistent lighting control. “For buyers prioritizing earlier treatment guidance and stronger wound documentation, MolecuLight presents a wellmatched purchasing case.” Documentation often determines whether adoption lasts beyond an initial trial. Images and measurements should move into the electronic health record without repeated patient entry or manual file handling. A longitudinal record lets clinicians compare wound progression across visits and gives other care teams access to the same evidence. It also strengthens audit documentation and reimbursement support. Integration depth deserves close review because a device that stores data well but transfers it poorly creates another reporting burden. Training is the final practical test. Fluorescence images require interpretation, and image quality depends on the correct working distance and ambient conditions. Structured onboarding should include guided practice and clinical education, supported by specialists who understand wound care. Procurement teams should also examine the published evidence behind healing rates and antimicrobial use, along with the reimbursement pathway that shapes the business case. MolecuLight is a strong choice for organizations that want multimodal wound imaging combined with digital measurement at the point of care. Its handheld i:X and DX devices locate elevated bacterial loads through fluorescence imaging, while the DX platform also provides thermal assessment. Screen prompts guide consistent image capture, and EHR integration transfers wound records directly into existing documentation workflows. Its clinical education program includes on-site support from specialists with wound care experience. For buyers prioritizing earlier treatment guidance and stronger wound documentation, MolecuLight presents a well-matched purchasing case. ...Read more
MINNEAPOLIS - Peytant Solutions  Inc., a medical technology company pioneering the use of amnion-based covered scaffolds for the treatment of luminal disease, announces the appointment of Craig Walker, MD as Chief Medical Officer. Dr. Walker, a globally recognized key opinion leader, joins Peytant with a distinguished combination of clinical practice, medical research, and product development experience and will oversee all current and future clinical applications of Peytant’s initial flagship product, the AMStent® Tracheobronchial Covered Stent System. Dr. Walker is board certified in internal medicine, cardiovascular disease, and interventional cardiology. He is a fellow of the American College of Cardiology, American College of Physicians, American Society of Cardiovascular Interventionists, International College of Angiology, Society for Cardiac Angiography and Interventions, American College of Chest Physicians, and Council on Clinical Cardiology. He attended Nicholls State University on academic scholarship and LSU Medical School in New Orleans. He completed a cardiology fellowship at Ochsner Foundation Hospital, where he was one of the first interventional fellows in the U.S. Dr. Walker subsequently performed a research fellowship at Harvard’s Brigham and Women’s Hospital in Boston. Dr. Walker is founder of New Cardiovascular Horizons, which provides multidisciplinary accredited conferences to advance the field of cardiovascular care. “It is my honor to have Dr. Walker join our executive management team as our Chief Medical Officer. Over the past three decades, I have had the privilege of collaborating and innovating with Dr. Walker on interventional technologies that have improved patient care. He’s a dedicated and curious scientist, real world physician, and successful entrepreneur with an unwavering commitment to improving the medical care,” stated John Schorgl, Peytant Solutions’ Chairman and Chief Executive Officer. “The AMStent system is a first-of-its-kind stent with an amnion-based covering to treat bronchial obstructions. I am optimistic that it will improve outcomes in patients with bronchial obstructions and I look forward to objectively assessing outcomes in patients and further evaluating additional clinical applications,” said Dr. Walker. The U.S. Food and Drug Administration (FDA) granted marketing authorization (clearance to market in the U.S. as a Class II device) for the AMStent® Tracheobronchial Covered Stent System in October 2024. The initial indication for the AMStent system is for use in the treatment of tracheobronchial strictures produced by malignant neoplasms in adult patients. The AMStent system is designed to treat pulmonary obstructions caused by cancer. In the U.S., lung cancer is the leading cause of cancer deaths, accounting for about one in five of all cancer deaths. Many patients with cancer in the lung develop malignant airway obstructions as the disease progresses. Palliative care is often pursued by increasing airflow in the trachea or tracheobronchial tree through dilation of the lumen. Once airflow is restored, it is routine to place airway stents in the passageway. The benefits of the AMStent system, as seen in validation data, include reduced migration, reduced local inflammation and granuloma formation, and reduced mucus accumulation and occlusion – so important to achieving the desired palliative relief for the patient.   ...Read more
Healthcare has traditionally been organized around episodes. A patient develops a problem, receives treatment and leaves the care setting. Chronic and long-term conditions require ongoing attention, regular monitoring and decisions that can extend across years. Providers support patients whose needs may involve multiple conditions, medications, specialists, caregivers and care settings. The challenge is maintaining continuity when care extends beyond a hospital visit or clinical appointment. Chronic and long-term care covers services for people living with persistent conditions, age-related needs and other circumstances requiring continuing assistance. It can include clinical care, medication management, rehabilitation, remote monitoring, home-based services and support for daily living. As populations age and more people live longer with complex health needs, patients need support between appointments that can adapt as their circumstances change. Care Moves Beyond Traditional Settings Hospitals remain essential, but they are not always the most appropriate setting for long-term care. Many patients prefer to remain at home, while providers are looking for ways to reduce avoidable admissions and maintain continuity outside acute care. Home and community-based models are gaining attention. Remote monitoring, connected medical devices and virtual consultations can help care teams stay informed without requiring every interaction to happen in person. These tools can support earlier intervention. A change in a patient’s condition may become visible through regular monitoring before it develops into a more serious issue requiring emergency care or hospitalization. Technology alone does not create better care. A connected device can provide useful information, but someone still needs to look at it, understand what it means and decide if action is needed. Digital tools need to work alongside clear clinical responsibility. Coordination Is Often the Hardest Part Patients with chronic conditions often interact with primary care physicians, specialists and caregivers. Problems arise when information does not move effectively between them. Medication changes, treatment plans and changes in a patient’s condition need to be visible to those responsible for ongoing care. Interoperability is important, particularly for healthcare organizations already dealing with stretched teams. Care coordination also requires a broader view of the patient. Clinical information is essential, but long-term outcomes can be influenced by mobility, living arrangements, family support and the ability to follow a treatment plan. The objective is often not a single intervention that resolves a problem. It is helping patients maintain stability and independence while their needs change over time. “Chronic and long-term care is moving away from isolated encounters. Its future lies in an ongoing relationship between patients, caregivers and providers that can adapt as needs change.” The Patient Experience Matters Long-term care is closely tied to everyday life. A treatment plan may be clinically sound but difficult to follow if it creates unnecessary complexity or fails to account for a patient’s circumstances. Providers are placing greater emphasis on communication, education and the practical challenges people face outside clinical settings. Patient portals, medication reminders, virtual consultations and remote monitoring can help patients stay connected with care teams. Accessibility remains important. Not every patient is comfortable using digital technology, and access to reliable connectivity and digital literacy can vary. Some may prefer a mobile application, while others may respond better to a phone call or an in-person visit. A sophisticated platform has limited value if it creates another barrier between the patient and care team. Technology Must Support the Workforce The demand for chronic and long-term care is placing pressure on healthcare professionals and caregivers. Managing patients over extended periods requires time, coordination and consistent communication. Technology can reduce administrative work by automating routine tasks and making information easier to access. Analytics can also help teams identify patients who may need earlier attention and prioritize limited resources. Still, automation has limits. Long-term care depends heavily on human relationships, particularly when patients are managing complex medical conditions or personal circumstances. Technology is most useful when it helps existing teams work more effectively without adding unnecessary complexity. Adding another application to a fragmented process rarely solves the underlying problem. Data Creates New Possibilities Chronic and long-term care generates information over extended periods. Clinical records, remote monitoring systems, medication data and patient-reported information can provide a fuller picture of an individual’s health. Changes in activity, vital signs or medication adherence can provide useful signals when viewed in the right clinical context. Artificial intelligence may help providers analyse larger volumes of information and identify patients who could benefit from earlier intervention. Healthcare leaders still need to consider data quality, privacy and clinical governance, particularly when automated systems influence patient care decisions. Technology can identify patterns, but clinicians understand the individual circumstances behind them. Human judgment remains central. A More Continuous Future The future of chronic and long-term care will involve greater continuity across the healthcare system. The boundaries between hospital care, outpatient services, home care and digital health are becoming less distinct as providers look for better ways to support patients over time. Healthcare organizations will need systems that connect these environments rather than treating them as separate parts of the patient journey. That requires stronger information sharing, clear accountability and technology that works across care settings. Long-term care is also about more than clinical outcomes. Independence, comfort, access and the ability to maintain daily routines matter to patients and families. Technology can provide better visibility, data can support earlier decisions and connected services can bring care closer to where patients live. Chronic and long-term care is moving away from isolated encounters. Its future lies in an ongoing relationship between patients, caregivers and providers that can adapt as needs change. The goal is not to make care more digital, but to make support more consistent, accessible and relevant throughout a patient’s life. ...Read more
Decontamination has to compete with everything else happening inside a facility. A hospital cannot put room turnover on hold for lengthy treatments. Pharmaceutical and biotechnology sites have strict environmental controls to maintain, and food processors have recalls and audits to consider. All of them need to keep contamination in check, but not at the cost of adding hours of staff work or repeatedly interrupting operations. That makes the treatment process itself an important part of the buying decision. Microbial reduction remains fundamental. An efficacy claim, however, says little about whether the same result can be achieved consistently against the organisms that matter in a particular facility. Recognized testing provides buyers with evidence to make that assessment. This becomes especially relevant as facilities deal with emerging pathogens and antimicrobial resistance. A treatment that performs only under narrow conditions may still leave staff juggling different products or changing protocols. For routine use, repeatability matters. “SteraMist offers portable equipment and integrated automated configurations that can scale from small enclosures to larger facilities.” So does the amount of work involved. Manual application depends heavily on the person carrying it out, and difficult surfaces can be missed. Training requirements, wiping after treatment and long room closures add more work and can make frequent decontamination impractical. Looking only at application time can therefore be misleading. Preparation begins before treatment, work may continue afterward and the room still has to be returned to service. Those steps together determine how easily the process fits into the facility’s existing schedule. Then there is everything that has to remain in the room. Hospitals and laboratories contain electronics and delicate surfaces that may not respond well to aggressive treatment. Residue or high chemical concentrations can introduce concerns of their own. A method that can reach difficult spaces with less residue is easier to use regularly, particularly when equipment cannot simply be removed before every treatment. “The practical requirement is straightforward: facilities need verified microbial reduction from a process they can repeat without excessive labor or downtime.” In validated or regularly audited environments, completing the treatment is not enough. Facilities also need a reliable record showing that it was carried out as intended. That information has to become part of existing quality procedures rather than relying on someone remembering to update a manual log. Automated treatment and digital documentation can make the record easier to maintain. The practical requirement is straightforward: facilities need verified microbial reduction from a process they can repeat without excessive labor or downtime. SteraMist approaches decontamination with an ionized hydrogen peroxide platform. Its 7.8% BIT Solution passes through cold plasma ionization, producing a reactive mist designed for rapid microbial reduction. Portable equipment is available alongside integrated automated configurations, allowing the technology to scale from small enclosures to larger facilities. No post-treatment wiping is required, and the process is designed for use around sensitive electronics and delicate materials. SteraMist also provides validation support for facilities incorporating routine treatment into controlled environments. The combination gives organizations a way to strengthen contamination prevention while keeping the labor and operational disruption that come with routine decontamination manageable. ...Read more